Shulamiet Wittebol

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Journal of Clinical Oncology · 2012 · 826 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Henk M. Lokhorst, Bronno van der Holt, Sonja Zweegman et al. · Blood · 2009 · 275 citations · Full text

Medicine, Hematology, Oncology +17

Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

Pierre W. Wijermans, M. Ronald Schaafsma, Fabian Termorshuizen et al. · Journal of Clinical Oncology · 2010 · 262 citations

Medicine, Oncology, Pharmacotherapy +17

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study

Henk M. Lokhorst, Bronno van der Holt, Jan J. Cornelissen et al. · Blood · 2012 · 104 citations · Full text

Medicine, Hematology, Oncology +11

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Blood Cancer Journal · 2011 · 99 citations · Full text

Medicine, Oncology, Pharmacotherapy +17